Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - The report reviews Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics and enlists all their major and minor projects - The report assesses Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Overview 8 Therapeutics Development 9 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Stage of Development 9 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Therapy Area 10 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Indication 11 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Companies 15 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Universities/Institutes 18 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Therapeutics Assessment 20 Assessment by Monotherapy/Combination Products 20 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Companies Involved in Therapeutics Development 27 Aptevo Therapeutics Inc 27 ARMO Biosciences, Inc. 28 BioMAS Ltd. 29 Biotest AG 30 enGene, Inc 31 Intrexon Corporation 32 LEO Pharma A/S 33 Merck & Co., Inc. 34 P2D Bioscience 35 Pfizer Inc. 36 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Drug Profiles 37 AM-0010 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 ANV-103 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 Diabetes - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Biologic to Target Insulin Receptor and IL-10 for Type 1 Diabetes - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 BT-063 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 CB-0602 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 CTLA-4 X mono-IL-10 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Dekavil - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 EG-10 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 EG-12 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Elmyelin - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Gene Therapy to Activate Interleukin-10 for ALS - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 LEO-32731 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 MK-1966 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 PD-2244 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Synthetic Peptides to Inhibit IL-10 and IFN Gamma for Cancer, Viral Infections and Inflammatory Diseases - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 XT-101 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 XT-150 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Dormant Projects 61 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Discontinued Products 64 Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Featured News & Press Releases 65 Sep 26, 2016: ARMO BioSciences Announces Data Presentations at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 65 Aug 15, 2016: ARMO BioSciences Announces Publication of AM0010 Clinical Data in Advanced Solid Tumor Patients in Journal of Clinical Oncology 66 Jun 06, 2016: ARMO BioSciences AM0010 Demonstrates Promising Clinical Data as an Immuno-oncology Monotherapy and in Combination with an Anti-PD-1 Checkpoint Inhibitor in Advanced Solid Tumors, Including Immune-Resistant Cancers 67 Apr 20, 2016: ARMO BioSciences Announces AM0010 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting in June 2016 68 Mar 31, 2016: Xalud Therapeutics Discovers Potential Solution for Opioid Abuse Crisis 69 Mar 16, 2016: ARMO BioSciences to Present New Clinical Trial Results for AM0010 at Upcoming Medical Conferences 70 Jan 08, 2016: ARMO BioSciences to Present at the 34th Annual J.P. Morgan HealthCare Conference 70 Oct 30, 2015: ARMO BioSciences Presents Positive Phase 1 Trial Results of AM0010 at Upcoming Medical Conferences 71 Oct 06, 2015: Biotest reaches the next milestone in the clinical development of its monoclonal antibody BT-063 by starting the clinical phase IIa trial in the indication systemic lupus erythematosus 71 Jun 01, 2015: ARMO BioSciences Announces Efficacy and Safety Data for Immuno-Oncology Program with Novel Mechanism of Action 72 May 13, 2015: ARMO BioSciences Announces Presentation on Promising Immuno-Oncology Program at 2015 ASCO Annual Meeting 73 Jun 23, 2014: Cytovance Biologics selected for GMP manufacture of AM0010 for ARMO BioSciences 73 Nov 25, 2013: ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy 73 Apr 11, 2012: University Of Leuven And ActoGeniX Announce Study Results Of ActoBiotic In Treatment Of Type 1 Diabetes 74 Sep 30, 2009: Biotest AG Announces Initiation of Clinical development of BT-063 75 Appendix 76 Methodology 76 Coverage 76 Secondary Research 76 Primary Research 76 Expert Panel Validation 76 Contact Us 76 Disclaimer 77
List of Tables
Number of Products under Development for, H2 2016 9 Number of Products under Development by Therapy Area, H2 2016 10 Number of Products under Development by Indication, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Early Stage Products, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H2 2016 18 Products under Investigation by Universities/Institutes, H2 2016 19 Assessment by Monotherapy/Combination Products, H2 2016 20 Number of Products by Stage and Mechanism of Action, H2 2016 22 Number of Products by Stage and Route of Administration, H2 2016 24 Number of Products by Stage and Molecule Type, H2 2016 26 Pipeline by Aptevo Therapeutics Inc, H2 2016 27 Pipeline by ARMO Biosciences, Inc., H2 2016 28 Pipeline by BioMAS Ltd., H2 2016 29 Pipeline by Biotest AG, H2 2016 30 Pipeline by enGene, Inc, H2 2016 31 Pipeline by Intrexon Corporation, H2 2016 32 Pipeline by LEO Pharma A/S, H2 2016 33 Pipeline by Merck & Co., Inc., H2 2016 34 Pipeline by P2D Bioscience, H2 2016 35 Pipeline by Pfizer Inc., H2 2016 36 Dormant Projects, H2 2016 61 Dormant Projects (Contd..1), H2 2016 62 Dormant Projects (Contd..2), H2 2016 63 Discontinued Products, H2 2016 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
